BriaCell Awarded New Zealand Patent for its Whole Cell Technology
PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT)...
immunotherapy
TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call
Conference Call and Webcast Scheduled for Tuesday August 12, 2025 at 4:30 PMWESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI)...
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its...
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage...
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b...
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs) Multivalent technology enables simultaneous...
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Mid-year report of combination therapy demonstrates promising signs of both no significant toxicity and superior PFS and OSOCALA, Fla., July...
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
IMUNON Announces Stock Dividend Boosting Shareholder Value
Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July...
OncoC4 Announces New Preclinical Data Highlighting ONC-841, a Novel SIGLEC 10 Antibody, as a Potential New Class of Therapeutics for Alzheimer’s Disease
SIGLEC 10 identified as a genetic driver for amyloid plaque formation in mice ONC-841 blockade reduced amyloid plaques, normalized microglia...
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
SYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage...
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to...
Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered...
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the...
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
Basel, 24 July 2025 Group sales grew by 7%1 at constant exchange rates (CER; 4% in CHF), driven by strong...
Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development in Septic Shock
Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development in Septic Shock Published in Intensive Care Medicine, Inotrem’s results...
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”)...
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”)...
IMUNON Announces Reverse Stock Split
LAWRENCEVILLE, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of...